Growth hormone responses to cholinergically active drugs in patients with dementia of the Alzheimer type

E. Lamperti, D. Cocchi, E. A. Parati, T. Caraceni, E. E. Muller

Research output: Contribution to journalArticle

Abstract

Patients with dementia of the Alzheimer type (DAT) reportedly have reduced concentrations and function of some brain messengers, particularly acetylcholine and somatostatin, not only in the cerebral cortex, but also in subcortical structures, e.g., the hippocampus and the hypothalamus. We wished to determine the responsive pattern of DAT patients to neurohormonal and pharmacologic probes affecting growth hormone (GH) release through an interaction with hypothalamic cholinergic and somatostatinergic (SS) neurons. In 10 DAT patients, pyridostigmine (120 mg orally, p.o.), an inhibitor of acetylcholinesterase, induced an increase in GH levels similar to that elicited by the drug in age-matched controls. In 9 DAT patients, administration of GH-releasing hormone (GHRH, 1 μg/kg body weight, intravenously, i.v.) induced an increase in plasma GH not different from that evidenced in control subjects. In DAT patients the GHRH-induced GH increase was completely inhibited by pretreatment with atropine (1 mg intramuscularly, i.m., 15 min before administration of GHRH). These findings are considered to indicate that in DAT patients, hypothalamic cholinergic and somatostatinergic neurons involved in control of somatotropic function are preserved.

Original languageEnglish
Pages (from-to)44-52
Number of pages9
JournalAlzheimer Disease and Associated Disorders
Volume6
Issue number1
Publication statusPublished - 1992

Fingerprint

Growth Hormone
Alzheimer Disease
Pharmaceutical Preparations
Cholinergic Neurons
Pyridostigmine Bromide
Growth Hormone-Releasing Hormone
Cholinesterase Inhibitors
Somatostatin
Atropine
Cerebral Cortex
Hypothalamus
Acetylcholine
Hippocampus
Body Weight
Brain

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Growth hormone responses to cholinergically active drugs in patients with dementia of the Alzheimer type. / Lamperti, E.; Cocchi, D.; Parati, E. A.; Caraceni, T.; Muller, E. E.

In: Alzheimer Disease and Associated Disorders, Vol. 6, No. 1, 1992, p. 44-52.

Research output: Contribution to journalArticle

@article{15634d1626264b57b2e41530ffe05f36,
title = "Growth hormone responses to cholinergically active drugs in patients with dementia of the Alzheimer type",
abstract = "Patients with dementia of the Alzheimer type (DAT) reportedly have reduced concentrations and function of some brain messengers, particularly acetylcholine and somatostatin, not only in the cerebral cortex, but also in subcortical structures, e.g., the hippocampus and the hypothalamus. We wished to determine the responsive pattern of DAT patients to neurohormonal and pharmacologic probes affecting growth hormone (GH) release through an interaction with hypothalamic cholinergic and somatostatinergic (SS) neurons. In 10 DAT patients, pyridostigmine (120 mg orally, p.o.), an inhibitor of acetylcholinesterase, induced an increase in GH levels similar to that elicited by the drug in age-matched controls. In 9 DAT patients, administration of GH-releasing hormone (GHRH, 1 μg/kg body weight, intravenously, i.v.) induced an increase in plasma GH not different from that evidenced in control subjects. In DAT patients the GHRH-induced GH increase was completely inhibited by pretreatment with atropine (1 mg intramuscularly, i.m., 15 min before administration of GHRH). These findings are considered to indicate that in DAT patients, hypothalamic cholinergic and somatostatinergic neurons involved in control of somatotropic function are preserved.",
author = "E. Lamperti and D. Cocchi and Parati, {E. A.} and T. Caraceni and Muller, {E. E.}",
year = "1992",
language = "English",
volume = "6",
pages = "44--52",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Growth hormone responses to cholinergically active drugs in patients with dementia of the Alzheimer type

AU - Lamperti, E.

AU - Cocchi, D.

AU - Parati, E. A.

AU - Caraceni, T.

AU - Muller, E. E.

PY - 1992

Y1 - 1992

N2 - Patients with dementia of the Alzheimer type (DAT) reportedly have reduced concentrations and function of some brain messengers, particularly acetylcholine and somatostatin, not only in the cerebral cortex, but also in subcortical structures, e.g., the hippocampus and the hypothalamus. We wished to determine the responsive pattern of DAT patients to neurohormonal and pharmacologic probes affecting growth hormone (GH) release through an interaction with hypothalamic cholinergic and somatostatinergic (SS) neurons. In 10 DAT patients, pyridostigmine (120 mg orally, p.o.), an inhibitor of acetylcholinesterase, induced an increase in GH levels similar to that elicited by the drug in age-matched controls. In 9 DAT patients, administration of GH-releasing hormone (GHRH, 1 μg/kg body weight, intravenously, i.v.) induced an increase in plasma GH not different from that evidenced in control subjects. In DAT patients the GHRH-induced GH increase was completely inhibited by pretreatment with atropine (1 mg intramuscularly, i.m., 15 min before administration of GHRH). These findings are considered to indicate that in DAT patients, hypothalamic cholinergic and somatostatinergic neurons involved in control of somatotropic function are preserved.

AB - Patients with dementia of the Alzheimer type (DAT) reportedly have reduced concentrations and function of some brain messengers, particularly acetylcholine and somatostatin, not only in the cerebral cortex, but also in subcortical structures, e.g., the hippocampus and the hypothalamus. We wished to determine the responsive pattern of DAT patients to neurohormonal and pharmacologic probes affecting growth hormone (GH) release through an interaction with hypothalamic cholinergic and somatostatinergic (SS) neurons. In 10 DAT patients, pyridostigmine (120 mg orally, p.o.), an inhibitor of acetylcholinesterase, induced an increase in GH levels similar to that elicited by the drug in age-matched controls. In 9 DAT patients, administration of GH-releasing hormone (GHRH, 1 μg/kg body weight, intravenously, i.v.) induced an increase in plasma GH not different from that evidenced in control subjects. In DAT patients the GHRH-induced GH increase was completely inhibited by pretreatment with atropine (1 mg intramuscularly, i.m., 15 min before administration of GHRH). These findings are considered to indicate that in DAT patients, hypothalamic cholinergic and somatostatinergic neurons involved in control of somatotropic function are preserved.

UR - http://www.scopus.com/inward/record.url?scp=0026748263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026748263&partnerID=8YFLogxK

M3 - Article

C2 - 1605943

AN - SCOPUS:0026748263

VL - 6

SP - 44

EP - 52

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - 1

ER -